Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAPRO-3
2021-000248-23Phase 3Active
- Sponsor
- Pfizer
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Talazoparib + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Investigator-assessed radiographic progression-free survival. Started Apr 2021; status: active.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-000248-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000248-23.